Buyback plans and results shaped Kalbe Farma stock review
Published on 10/17/2026 at 11:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDated developments and next session
- Buyback coverage was dated October 7, 2026 and cited IDR 500 billion.
- First-half revenue was reported at 14.05 percent growth on October 7, 2026.
- October 19, 2026 is the next Xetra session.
Buyback plans and first-half results shaped the Kalbe Farma stock review through October 9, 2026, based on dated entries in the weekly record.
Market context: Market report IDX Composite.
The week in figures
The weekly record cited an IDR 500 billion buyback plan and first-half revenue growth of 14.05 percent. The dated entries covered October 7 through October 9, 2026.
Chronology of the week
On October 7, 2026, the record cited first-half revenue growth of 14.05 percent and a decline in net income of 2.74 percent. It also listed an IDR 500 billion buyback plan.
On October 8, 2026, the record listed an IDR 775.00 Jakarta quote and described the related first-half figures. On October 9, 2026, it recorded an EUR 0.04 Lang & Schwarz quote.
Weekend trading
The Lang & Schwarz page for Kalbe Farma carried a prior quote record dated October 16, 2026. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Kalbe Farma stock.
Dates of the coming week
The next Xetra session is October 19, 2026. The weekly record also provides dated context from October 7 through October 9, 2026.
